



*Effective treatments for
common skin disorders*

PRESS RELEASE FEBRUARY 27, 2009

MOBERG DERMA ACQUIRES PHARMACEUTICAL PROJECTS FROM ZELMIC

Moberg Derma AB today announces the acquisition of two pharmaceutical projects in preclinical phase from Zelmic AB (Lund, Sweden). Zelmic will assist Moberg Derma in the future development of the projects. The two companies also agreed on a long term collaboration on future development projects. Financial terms were not disclosed.

"We have worked with the Zelmic team for some time and are impressed by their innovation and development capabilities. These projects broaden Moberg Derma's portfolio and add product candidates of substantial value", says Peter Wolpert, CEO of Moberg Derma AB and adds. "This is our first acquisition. External opportunities and acquisitions are an integral part of our expansion strategy."

"It is invaluable for Zelmic to collaborate with Moberg Derma who is a commercially focused partner. Moberg Derma has the capacity to further develop and commercialize our projects. The two companies has complementing know-how and experience which provide considerable synergies", says Åke Lindahl, CEO of Zelmic AB.

Contact Moberg Derma

Peter Wolpert, President and CEO

Telephone: +46 8 522 307 08

Mobile: +46 70 735 71 35

E-mail: peter.wolpert@mobergderma.se

Contact Zelmic

Åke Lindahl, President and CEO

Telephone: +46 46 161 240

E-mail: al@zelmic.se

About Moberg Derma

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of common skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se

About Zelmic

Zelmic AB, Lund, Sweden, is a CRO that offers new product opportunities and contract services to pharmaceutical companies. The focus and expertise of Zelmic is topical and local delivery in dermatology and proctology as well as local delivery of protein drugs. Zelmic has experience of developing topical products for indications such as acne, actinic keratosis, atopic dermatitis, psoriasis and fungal infections. For further information, please visit: www.zelmic.se